SHANGHAI — Two Chinese antiviral medicine for COVID-19 mainly developed by the Shanghai Institute of Materia Medica under the Chinese Academy of Sciences (CAS) have commenced human trials overseas.

One candidate, coded VV116, is an oral anti-COVID-19 nucleoside drug that has yielded promising results in animal models.…